{"id":349707,"date":"2025-08-25T18:14:03","date_gmt":"2025-08-25T18:14:03","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-immunovant\/"},"modified":"2025-08-25T18:14:03","modified_gmt":"2025-08-25T18:14:03","slug":"how-to-buy-immunovant","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/","title":{"rendered":"How to buy Immunovant, Inc. (IMVT) shares &#8211; Investment in Immunovant, Inc. (IMVT) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-349707","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy Immunovant, Inc. (IMVT) Shares - Investment in Immunovant, Inc. (IMVT) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy Immunovant, Inc. (IMVT) Shares - Investment in Immunovant, Inc. (IMVT) Stock"},"description":"Learn how to buy Immunovant, Inc. (IMVT) shares and invest in this clinical-stage biotech company. Discover current stock performance, price predictions, and trading strategies for 2025.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to buy Immunovant, Inc. (IMVT) shares and invest in this clinical-stage biotech company. Discover current stock performance, price predictions, and trading strategies for 2025."},"intro":"Thinking about investing in the future of autoimmune disease treatments? Immunovant represents one of the most exciting clinical-stage biotech opportunities of 2025. With six potentially registrational trials underway and a cash runway through 2027, this company could revolutionize how we treat conditions like Graves' disease and rheumatoid arthritis. Let's explore why IMVT stock deserves your attention.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in the future of autoimmune disease treatments? Immunovant represents one of the most exciting clinical-stage biotech opportunities of 2025. With six potentially registrational trials underway and a cash runway through 2027, this company could revolutionize how we treat conditions like Graves' disease and rheumatoid arthritis. Let's explore why IMVT stock deserves your attention."},"body_html":"<h2>\ud83d\udcc8 Immunovant Stock Analysis: Current Price and Market Position<\/h2> <p>As of August 25, 2025, Immunovant, Inc. (IMVT) trades at <strong>$15.24<\/strong> on NASDAQ. This price represents a fascinating entry point considering the company's clinical progress and analyst optimism.<\/p> <p><strong>Mark Your Calendar: September 2025 is Critical!<\/strong><\/p> <p>The American Thyroid Association Annual Meeting in September 2025 could be a game-changer for IMVT shareholders. Immunovant will present remission data from their batoclimab proof-of-concept study in Graves' disease (<a href=\"https:\/\/www.immunovant.com\/investors\/news-events\/press-releases\/detail\/66\/immunovant-announces-oral-presentation-of-late-breaking\">Immunovant Press Release<\/a>).<\/p> <p>Historical data shows these medical conference presentations can move biotech stocks dramatically. When Immunovant reported positive Phase 2a results in September 2024 showing 76% response rates in Graves' disease patients, the stock saw significant volatility. The upcoming September 2025 data could trigger even bigger moves given it's proof-of-concept remission data.<\/p> <p><strong>6-Month Price Journey: Rollercoaster with Recovery Signs<\/strong><\/p> <p>Immunovant has taken investors on quite a ride in 2025:<\/p> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr> <th>Month<\/th> <th>High<\/th> <th>Low<\/th> <th>% Change<\/th> <th>Key Development<\/th> <\/tr> <\/thead> <tbody> <tr> <td>February<\/td> <td>$23.11<\/td> <td>$19.07<\/td> <td>-5.24%<\/td> <td>Early year consolidation<\/td> <\/tr> <tr> <td>March<\/td> <td>$20.70<\/td> <td>$16.72<\/td> <td>-17.04%<\/td> <td>Broad market biotech weakness<\/td> <\/tr> <tr> <td>April<\/td> <td>$17.09<\/td> <td>$12.72<\/td> <td>-5.50%<\/td> <td>Reached 52-week low<\/td> <\/tr> <tr> <td>May<\/td> <td>$16.44<\/td> <td>$13.36<\/td> <td>-8.05%<\/td> <td>Continued pressure<\/td> <\/tr> <tr> <td>June<\/td> <td>$17.14<\/td> <td>$14.58<\/td> <td>+7.74%<\/td> <td>First signs of recovery<\/td> <\/tr> <tr> <td>July<\/td> <td>$19.06<\/td> <td>$15.31<\/td> <td>+5.94%<\/td> <td>Continued upward momentum<\/td> <\/tr> <\/tbody> <\/table> <p>The stock declined approximately 37% from January highs to May lows but has shown encouraging recovery of nearly 15% from the April lows. Volume patterns suggest institutional accumulation during the weakness.<\/p> [cta_green text=\"Start trading\"]<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <p>Based on current analyst consensus and clinical milestones, here's what to expect:<\/p> <p><strong>2025 Year-End:<\/strong> $18-22 range (potential 18-44% upside)<br> The September ATA meeting data could be the catalyst that pushes IMVT toward the higher end of this range.<\/p> <p><strong>2026 Forecast:<\/strong> $30-38 target range<br> Analysts at <a href=\"https:\/\/www.tipranks.com\/stocks\/imvt\/forecast\">TipRanks<\/a> project a $37.83 average price target, representing 148% upside potential.<\/p> <p><strong>2028 Outlook:<\/strong> $45-65 potential range<br> By 2028, multiple clinical readouts across six indications could drive substantial value if trials succeed.<\/p> <p><strong>2030 Vision:<\/strong> $50-80 long-term potential<br> Stockscan.io projects an average price of $64.16 by 2030 if execution continues successfully.<\/p> <p><strong>Verdict: STRONG BUY for risk-tolerant investors<\/strong><br> The risk-reward ratio appears highly favorable given the cash runway through 2027 and multiple clinical catalysts.<\/p> <h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2> <p><strong>Risks to Consider:<\/strong><\/p> <ul> <li>Clinical trial failures (biotech's eternal risk)<\/li> <li>Regulatory hurdles for novel autoimmune treatments<\/li> <li>Cash burn rate of ~$100M quarterly<\/li> <li>High volatility typical of pre-revenue biotech<\/li> <li>Competitive landscape in FcRn inhibitor space<\/li> <\/ul> <p><strong>Green Lights for 2025:<\/strong><\/p> <ul> <li>Six potentially registrational trials underway<\/li> <li>$714M cash runway through 2027 (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/05\/29\/3090173\/0\/en\/Immunovant-Provides-Corporate-Updates-and-Reports-Financial-Results-for-the-Fourth-Quarter-and-Fiscal-Year-Ended-March-31-2025.html\">Q4 FY2025 Report<\/a>)<\/li> <li>September 2025 Graves' disease data catalyst<\/li> <li>New leadership with Eric Venker as CEO<\/li> <li>Industry trend: autoimmune disease market growing at 9% CAGR<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Start Small<\/strong> - Allocate no more than 2-5% of your portfolio to high-risk biotech like IMVT<\/li> <li><strong>Dollar-Cost Average<\/strong> - Buy in increments rather than one lump sum to reduce timing risk<\/li> <li><strong>Set Alert for September<\/strong> - The ATA meeting could provide excellent entry points on volatility<\/li> <li><strong>Think Long-Term<\/strong> - Biotech investing requires patience through clinical milestones<\/li> <\/ol> <p>Humorous trader wisdom: \"Buying IMVT now is like getting backstage passes to a concert that hasn't been announced yet. You might wait through some boring opening acts, but when the headliner hits the stage...\"<\/p> <h2>\u2705 How to Buy Immunovant, Inc. (IMVT) Shares - Step by Step<\/h2> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr> <th>Step<\/th> <th>Action<\/th> <th>Why It Matters<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Choose a Trading Platform<\/td> <td>Ensure it offers NASDAQ listings and fractional shares<\/td> <\/tr> <tr> <td>2<\/td> <td>Complete Account Funding<\/td> <td>Start with an amount you're comfortable risking<\/td> <\/tr> <tr> <td>3<\/td> <td>Search \"IMVT\"<\/td> <td>Use the exact ticker symbol for Immunovant<\/td> <\/tr> <tr> <td>4<\/td> <td>Select Order Type<\/td> <td>Use limit orders to control your entry price<\/td> <\/tr> <tr> <td>5<\/td> <td>Review and Confirm<\/td> <td>Double-check order details before executing<\/td> <\/tr> <tr> <td>6<\/td> <td>Monitor Your Position<\/td> <td>Set price alerts for important levels<\/td> <\/tr> <tr> <td>7<\/td> <td>Plan Your Exit Strategy<\/td> <td>Decide profit-taking and stop-loss levels in advance<\/td> <\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2> <p>For those looking to start their investment journey, Pocket Option offers several advantages:<\/p> <ul> <li><strong>Minimum deposit of just $5<\/strong> - Perfect for testing strategies with minimal risk<\/li> <li><strong>1-minute KYC process<\/strong> - Upload any ID document and start trading immediately<\/li> <li><strong>100+ withdrawal methods<\/strong> - Flexibility with crypto, e-wallets, and bank cards<\/li> <li><strong>Fractional share trading<\/strong> - Buy portions of expensive stocks like IMVT<\/li> <\/ul> <p>The platform's user-friendly interface makes it ideal for beginners who want to build confidence before committing larger amounts.<\/p> <h2>\ud83c\udf0d Immunovant in 2025: Autoimmune Disease Innovator<\/h2> <p>Immunovant stands at the forefront of autoimmune disease treatment development. The company's lead asset, IMVT-1402, represents a potentially best-in-class FcRn inhibitor that could transform treatment for millions suffering from conditions like Graves' disease, rheumatoid arthritis, and myasthenia gravis.<\/p> <ul> <li><strong>Current Market Position:<\/strong> Clinical-stage biotech with six active development programs<\/li> <li><strong>Cash Runway:<\/strong> Approximately $714 million through expected 2027 data readouts<\/li> <li><strong>Leadership:<\/strong> Dr. Eric Venker as CEO since April 2025 transition<\/li> <\/ul> <p><strong>Interesting Fact:<\/strong> In June 2025, Immunovant became one of the few biotech companies to simultaneously initiate two potentially registrational trials - for Graves' disease AND Sj\u00f6gren's disease. This aggressive parallel development strategy is relatively rare in the industry and demonstrates confidence in their platform technology.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Immunovant Stock Analysis: Current Price and Market Position<\/h2>\n<p>As of August 25, 2025, Immunovant, Inc. (IMVT) trades at <strong>$15.24<\/strong> on NASDAQ. This price represents a fascinating entry point considering the company&#8217;s clinical progress and analyst optimism.<\/p>\n<p><strong>Mark Your Calendar: September 2025 is Critical!<\/strong><\/p>\n<p>The American Thyroid Association Annual Meeting in September 2025 could be a game-changer for IMVT shareholders. Immunovant will present remission data from their batoclimab proof-of-concept study in Graves&#8217; disease (<a href=\"https:\/\/www.immunovant.com\/investors\/news-events\/press-releases\/detail\/66\/immunovant-announces-oral-presentation-of-late-breaking\">Immunovant Press Release<\/a>).<\/p>\n<p>Historical data shows these medical conference presentations can move biotech stocks dramatically. When Immunovant reported positive Phase 2a results in September 2024 showing 76% response rates in Graves&#8217; disease patients, the stock saw significant volatility. The upcoming September 2025 data could trigger even bigger moves given it&#8217;s proof-of-concept remission data.<\/p>\n<p><strong>6-Month Price Journey: Rollercoaster with Recovery Signs<\/strong><\/p>\n<p>Immunovant has taken investors on quite a ride in 2025:<\/p>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Month<\/th>\n<th>High<\/th>\n<th>Low<\/th>\n<th>% Change<\/th>\n<th>Key Development<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>February<\/td>\n<td>$23.11<\/td>\n<td>$19.07<\/td>\n<td>-5.24%<\/td>\n<td>Early year consolidation<\/td>\n<\/tr>\n<tr>\n<td>March<\/td>\n<td>$20.70<\/td>\n<td>$16.72<\/td>\n<td>-17.04%<\/td>\n<td>Broad market biotech weakness<\/td>\n<\/tr>\n<tr>\n<td>April<\/td>\n<td>$17.09<\/td>\n<td>$12.72<\/td>\n<td>-5.50%<\/td>\n<td>Reached 52-week low<\/td>\n<\/tr>\n<tr>\n<td>May<\/td>\n<td>$16.44<\/td>\n<td>$13.36<\/td>\n<td>-8.05%<\/td>\n<td>Continued pressure<\/td>\n<\/tr>\n<tr>\n<td>June<\/td>\n<td>$17.14<\/td>\n<td>$14.58<\/td>\n<td>+7.74%<\/td>\n<td>First signs of recovery<\/td>\n<\/tr>\n<tr>\n<td>July<\/td>\n<td>$19.06<\/td>\n<td>$15.31<\/td>\n<td>+5.94%<\/td>\n<td>Continued upward momentum<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The stock declined approximately 37% from January highs to May lows but has shown encouraging recovery of nearly 15% from the April lows. Volume patterns suggest institutional accumulation during the weakness.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<p>Based on current analyst consensus and clinical milestones, here&#8217;s what to expect:<\/p>\n<p><strong>2025 Year-End:<\/strong> $18-22 range (potential 18-44% upside)<br \/> The September ATA meeting data could be the catalyst that pushes IMVT toward the higher end of this range.<\/p>\n<p><strong>2026 Forecast:<\/strong> $30-38 target range<br \/> Analysts at <a href=\"https:\/\/www.tipranks.com\/stocks\/imvt\/forecast\">TipRanks<\/a> project a $37.83 average price target, representing 148% upside potential.<\/p>\n<p><strong>2028 Outlook:<\/strong> $45-65 potential range<br \/> By 2028, multiple clinical readouts across six indications could drive substantial value if trials succeed.<\/p>\n<p><strong>2030 Vision:<\/strong> $50-80 long-term potential<br \/> Stockscan.io projects an average price of $64.16 by 2030 if execution continues successfully.<\/p>\n<p><strong>Verdict: STRONG BUY for risk-tolerant investors<\/strong><br \/> The risk-reward ratio appears highly favorable given the cash runway through 2027 and multiple clinical catalysts.<\/p>\n<h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2>\n<p><strong>Risks to Consider:<\/strong><\/p>\n<ul>\n<li>Clinical trial failures (biotech&#8217;s eternal risk)<\/li>\n<li>Regulatory hurdles for novel autoimmune treatments<\/li>\n<li>Cash burn rate of ~$100M quarterly<\/li>\n<li>High volatility typical of pre-revenue biotech<\/li>\n<li>Competitive landscape in FcRn inhibitor space<\/li>\n<\/ul>\n<p><strong>Green Lights for 2025:<\/strong><\/p>\n<ul>\n<li>Six potentially registrational trials underway<\/li>\n<li>$714M cash runway through 2027 (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/05\/29\/3090173\/0\/en\/Immunovant-Provides-Corporate-Updates-and-Reports-Financial-Results-for-the-Fourth-Quarter-and-Fiscal-Year-Ended-March-31-2025.html\">Q4 FY2025 Report<\/a>)<\/li>\n<li>September 2025 Graves&#8217; disease data catalyst<\/li>\n<li>New leadership with Eric Venker as CEO<\/li>\n<li>Industry trend: autoimmune disease market growing at 9% CAGR<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Start Small<\/strong> &#8211; Allocate no more than 2-5% of your portfolio to high-risk biotech like IMVT<\/li>\n<li><strong>Dollar-Cost Average<\/strong> &#8211; Buy in increments rather than one lump sum to reduce timing risk<\/li>\n<li><strong>Set Alert for September<\/strong> &#8211; The ATA meeting could provide excellent entry points on volatility<\/li>\n<li><strong>Think Long-Term<\/strong> &#8211; Biotech investing requires patience through clinical milestones<\/li>\n<\/ol>\n<p>Humorous trader wisdom: &#8220;Buying IMVT now is like getting backstage passes to a concert that hasn&#8217;t been announced yet. You might wait through some boring opening acts, but when the headliner hits the stage&#8230;&#8221;<\/p>\n<h2>\u2705 How to Buy Immunovant, Inc. (IMVT) Shares &#8211; Step by Step<\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose a Trading Platform<\/td>\n<td>Ensure it offers NASDAQ listings and fractional shares<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete Account Funding<\/td>\n<td>Start with an amount you&#8217;re comfortable risking<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Search &#8220;IMVT&#8221;<\/td>\n<td>Use the exact ticker symbol for Immunovant<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Select Order Type<\/td>\n<td>Use limit orders to control your entry price<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Review and Confirm<\/td>\n<td>Double-check order details before executing<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Monitor Your Position<\/td>\n<td>Set price alerts for important levels<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Plan Your Exit Strategy<\/td>\n<td>Decide profit-taking and stop-loss levels in advance<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2>\n<p>For those looking to start their investment journey, Pocket Option offers several advantages:<\/p>\n<ul>\n<li><strong>Minimum deposit of just $5<\/strong> &#8211; Perfect for testing strategies with minimal risk<\/li>\n<li><strong>1-minute KYC process<\/strong> &#8211; Upload any ID document and start trading immediately<\/li>\n<li><strong>100+ withdrawal methods<\/strong> &#8211; Flexibility with crypto, e-wallets, and bank cards<\/li>\n<li><strong>Fractional share trading<\/strong> &#8211; Buy portions of expensive stocks like IMVT<\/li>\n<\/ul>\n<p>The platform&#8217;s user-friendly interface makes it ideal for beginners who want to build confidence before committing larger amounts.<\/p>\n<h2>\ud83c\udf0d Immunovant in 2025: Autoimmune Disease Innovator<\/h2>\n<p>Immunovant stands at the forefront of autoimmune disease treatment development. The company&#8217;s lead asset, IMVT-1402, represents a potentially best-in-class FcRn inhibitor that could transform treatment for millions suffering from conditions like Graves&#8217; disease, rheumatoid arthritis, and myasthenia gravis.<\/p>\n<ul>\n<li><strong>Current Market Position:<\/strong> Clinical-stage biotech with six active development programs<\/li>\n<li><strong>Cash Runway:<\/strong> Approximately $714 million through expected 2027 data readouts<\/li>\n<li><strong>Leadership:<\/strong> Dr. Eric Venker as CEO since April 2025 transition<\/li>\n<\/ul>\n<p><strong>Interesting Fact:<\/strong> In June 2025, Immunovant became one of the few biotech companies to simultaneously initiate two potentially registrational trials &#8211; for Graves&#8217; disease AND Sj\u00f6gren&#8217;s disease. This aggressive parallel development strategy is relatively rare in the industry and demonstrates confidence in their platform technology.<\/p>\n"},"faq":[{"question":"What exactly does Immunovant do?","answer":"Immunovant develops monoclonal antibody treatments for autoimmune diseases, with six clinical programs targeting conditions like Graves' disease, rheumatoid arthritis, and myasthenia gravis."},{"question":"Why is September 2025 important for IMVT stock?","answer":"The company presents remission data from their Graves' disease study at the American Thyroid Association meeting, which could significantly impact the stock price."},{"question":"How much cash does Immunovant have?","answer":"As of March 2025, they had approximately $714 million in cash, providing runway through expected 2027 clinical readouts."},{"question":"Is Immunovant profitable?","answer":"No, like most clinical-stage biotech companies, Immunovant is not yet profitable as they invest heavily in research and development."},{"question":"What's the biggest risk with investing in IMVT?","answer":"The primary risk is clinical trial failure - if their lead drug candidates don't show efficacy in trials, the stock could decline significantly."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"What exactly does Immunovant do?","answer":"Immunovant develops monoclonal antibody treatments for autoimmune diseases, with six clinical programs targeting conditions like Graves' disease, rheumatoid arthritis, and myasthenia gravis."},{"question":"Why is September 2025 important for IMVT stock?","answer":"The company presents remission data from their Graves' disease study at the American Thyroid Association meeting, which could significantly impact the stock price."},{"question":"How much cash does Immunovant have?","answer":"As of March 2025, they had approximately $714 million in cash, providing runway through expected 2027 clinical readouts."},{"question":"Is Immunovant profitable?","answer":"No, like most clinical-stage biotech companies, Immunovant is not yet profitable as they invest heavily in research and development."},{"question":"What's the biggest risk with investing in IMVT?","answer":"The primary risk is clinical trial failure - if their lead drug candidates don't show efficacy in trials, the stock could decline significantly."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy Immunovant, Inc. (IMVT) shares - Investment in Immunovant, Inc. (IMVT) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy Immunovant, Inc. (IMVT) shares - Investment in Immunovant, Inc. (IMVT) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T18:14:03+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy Immunovant, Inc. (IMVT) shares &#8211; Investment in Immunovant, Inc. (IMVT) stock\",\"datePublished\":\"2025-08-25T18:14:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/\"},\"wordCount\":15,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/\",\"name\":\"How to buy Immunovant, Inc. (IMVT) shares - Investment in Immunovant, Inc. (IMVT) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"datePublished\":\"2025-08-25T18:14:03+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy Immunovant, Inc. (IMVT) shares &#8211; Investment in Immunovant, Inc. (IMVT) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy Immunovant, Inc. (IMVT) shares - Investment in Immunovant, Inc. (IMVT) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/","og_locale":"en_US","og_type":"article","og_title":"How to buy Immunovant, Inc. (IMVT) shares - Investment in Immunovant, Inc. (IMVT) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T18:14:03+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy Immunovant, Inc. (IMVT) shares &#8211; Investment in Immunovant, Inc. (IMVT) stock","datePublished":"2025-08-25T18:14:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/"},"wordCount":15,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/","name":"How to buy Immunovant, Inc. (IMVT) shares - Investment in Immunovant, Inc. (IMVT) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","datePublished":"2025-08-25T18:14:03+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-immunovant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy Immunovant, Inc. (IMVT) shares &#8211; Investment in Immunovant, Inc. (IMVT) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":349748,"slug":"how-to-buy-immunovant","post_title":"Comment acheter des actions Immunovant, Inc. (IMVT) - Investir dans les actions Immunovant, Inc. (IMVT)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-immunovant\/"},"it_IT":{"locale":"it_IT","id":349747,"slug":"how-to-buy-immunovant","post_title":"Come acquistare azioni Immunovant, Inc. (IMVT) - Investire in azioni Immunovant, Inc. (IMVT)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-immunovant\/"},"pl_PL":{"locale":"pl_PL","id":349754,"slug":"how-to-buy-immunovant","post_title":"Jak kupi\u0107 akcje Immunovant, Inc. (IMVT) - Inwestycja w akcje Immunovant, Inc. (IMVT)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-immunovant\/"},"es_ES":{"locale":"es_ES","id":349753,"slug":"how-to-buy-immunovant","post_title":"C\u00f3mo comprar acciones de Immunovant, Inc. (IMVT) - Inversi\u00f3n en acciones de Immunovant, Inc. (IMVT)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-immunovant\/"},"th_TH":{"locale":"th_TH","id":349752,"slug":"how-to-buy-immunovant","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 Immunovant, Inc. (IMVT) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 Immunovant, Inc. (IMVT)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-immunovant\/"},"tr_TR":{"locale":"tr_TR","id":349750,"slug":"how-to-buy-immunovant","post_title":"Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Immunovant, Inc. (IMVT) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/"},"vt_VT":{"locale":"vt_VT","id":349751,"slug":"how-to-buy-immunovant","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Immunovant, Inc. (IMVT) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Immunovant, Inc. (IMVT)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-immunovant\/"},"pt_AA":{"locale":"pt_AA","id":349749,"slug":"how-to-buy-immunovant","post_title":"Como comprar a\u00e7\u00f5es da Immunovant, Inc. (IMVT) - Investimento em a\u00e7\u00f5es da Immunovant, Inc. (IMVT)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-immunovant\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/349707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=349707"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/349707\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334072"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=349707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=349707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=349707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}